DeepQure Inc.

DeepQure is a medical device startup on a mission to redefine cardiovascular disease treatment through innovation. We are advancing Renal Denervation (RDN) therapy with our HyperQure™ platform — the world’s first extravascular RDN solution for resistant hypertension. HyperQure's patented extravascular technology operates outside blood vessels, ensuring safety by eliminating vascular damage risks while achieving precise, complete denervation. This approach enhances both patient safety and long-term outcomes. As a global first-in-class innovation, HyperQure is leading clinical validation, with pioneering first-in-human trials in South Korea and FDA IDE approval, paving the way for U.S. trials. With 190 million adults affected by resistant hypertension and a $26.1 billion market, HyperQure is a critical solution to a global health crisis. Backed by over 10 scientific publications, its proven safety and efficacy are revolutionizing hypertension management. Shape the future of cardiovascular care with us!